{"disease":{"id":"transthyretin","name":"transthyretin"},"drugs":{"marketed":[{"drug_id":"tafamidis","indication_name":"Wild-type transthyretin cardiac amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"tafamidis","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":"1430.0","mechanism":"Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"tafamidis","indication_name":"Transthyretin related familial amyloid cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"tafamidis","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":"1430.0","mechanism":"Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"vutrisiran","indication_name":"Transthyretin familial amyloid polyneuropathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amvuttra","generic_name":"VUTRISIRAN","company_name":"Alnylam Pharmaceuticals","drug_phase":"marketed","molecular_target":"transthyretin (TTR) mRNA","drug_class":"Small Interfering RNA","quality_score":10,"revenue":"1100","mechanism":"Amvuttra works by silencing the production of abnormal TTR protein through RNA interference."},{"drug_id":"patisiran","indication_name":"Transthyretin familial amyloid polyneuropathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Onpattro","generic_name":"PATISIRAN","company_name":"Alnylam Pharmaceuticals","drug_phase":"marketed","molecular_target":"transthyretin (TTR) mRNA","drug_class":"Small Interfering RNA","quality_score":59,"revenue":"700","mechanism":"Onpattro works by silencing the production of abnormal TTR protein using small interfering RNA."},{"drug_id":"patisiran-sodium","indication_name":"Transthyretin familial amyloid polyneuropathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Onpattro","generic_name":"PATISIRAN SODIUM","company_name":"Alnylam Pharmaceuticals","drug_phase":"marketed","molecular_target":"transthyretin (TTR) mRNA","drug_class":"Small Interfering RNA","quality_score":10,"revenue":"700","mechanism":"Onpattro works by silencing the production of abnormal TTR protein through RNA interference."},{"drug_id":"acoramidis","indication_name":"cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Attruby","generic_name":"ACORAMIDIS","company_name":"Bridgebio Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Attruby works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"vyndamax","indication_name":"Transthyretin related familial amyloid cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"Tafamidis","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":null,"mechanism":"Vyndaqel stabilizes the Transthyretin protein, preventing its misfolding and aggregation into amyloid fibrils."},{"drug_id":"vyndamax","indication_name":"Wild-type transthyretin cardiac amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"Tafamidis","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":null,"mechanism":"Vyndaqel stabilizes the Transthyretin protein, preventing its misfolding and aggregation into amyloid fibrils."},{"drug_id":"eplontersen","indication_name":"polyneuropathy of hereditary transthyretin-mediated amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wainua","generic_name":"EPLONTERSEN","company_name":"Astrazeneca Ab","drug_phase":"marketed","molecular_target":"","drug_class":"Transthyretin-directed RNA Interaction [EPC]","quality_score":10,"revenue":null,"mechanism":"Wainua works by binding to the transthyretin RNA to prevent the production of the transthyretin protein."},{"drug_id":"eplontersen","indication_name":"Polyneuropathy of hereditary transthyretin-mediated amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wainua","generic_name":"EPLONTERSEN","company_name":"Astrazeneca Ab","drug_phase":"marketed","molecular_target":"","drug_class":"Transthyretin-directed RNA Interaction [EPC]","quality_score":10,"revenue":null,"mechanism":"Wainua works by binding to the transthyretin RNA to prevent the production of the transthyretin protein."},{"drug_id":"vyndaqel","indication_name":"Transthyretin related familial amyloid cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"Tafamidis Meglumine","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin (TTR)","drug_class":"Transthyretin stabilizer","quality_score":10,"revenue":null,"mechanism":"Tafamidis selectively stabilizes TTR tetramer by binding at thyroxine sites, slowing monomer dissociation."},{"drug_id":"vyndaqel","indication_name":"Wild-type transthyretin cardiac amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"Tafamidis Meglumine","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin (TTR)","drug_class":"Transthyretin stabilizer","quality_score":10,"revenue":null,"mechanism":"Tafamidis selectively stabilizes TTR tetramer by binding at thyroxine sites, slowing monomer dissociation."},{"drug_id":"tafamidis-test","indication_name":"Transthyretin related familial amyloid cardiomyopathy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"tafamidis-test","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":null,"mechanism":"Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"tafamidis-test","indication_name":"Wild-type transthyretin cardiac amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"tafamidis-test","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":null,"mechanism":"Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."}],"pipeline":[{"drug_id":"vyndamax-tafamidis-61mg","indication_name":"ATTR-CM (Transthyretin Amyloid Cardiomyopathy)","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndamax (tafamidis 61mg)","generic_name":"vyndamax-tafamidis-61mg","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"As prescribed in real world practice","quality_score":0,"revenue":null,"mechanism":"As prescribed in real world practice"},{"drug_id":"treatment-for-ttr-amyloidosis","indication_name":"Transthyretin (TTR) Amyloid Cardiomyopathy","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Treatment for TTR amyloidosis","generic_name":"treatment-for-ttr-amyloidosis","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"The usual adult dose is 80 mg of Tafamidis Meglumine orally once daily. The dose may be reduced if n","quality_score":null,"revenue":null,"mechanism":"The usual adult dose is 80 mg of Tafamidis Meglumine orally once daily. The dose may be reduced if n"},{"drug_id":"tafamidis-61-milligrams","indication_name":"Transthyretin Amyloid Cardiomyopathy","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tafamidis 61 milligrams","generic_name":"tafamidis-61-milligrams","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Tafamidis 61mg as provided in real-world practice","quality_score":null,"revenue":null,"mechanism":"Tafamidis 61mg as provided in real-world practice"}],"offLabel":[],"totalMarketed":14,"totalPipeline":3},"trials":{"data":[{"nct_id":"NCT06328075","title":"Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis","phase":"","overall_status":"UNKNOWN","enrollment_count":15000,"lead_sponsor_name":"Algalarrondo Vincent","has_results":false},{"nct_id":"NCT00628745","title":"Transthyretin Amyloidosis Outcome Survey (THAOS)","phase":"","overall_status":"COMPLETED","enrollment_count":6718,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03237494","title":"TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects","phase":"","overall_status":"COMPLETED","enrollment_count":5028,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false},{"nct_id":"NCT07235462","title":"A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT07358078","title":"DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT06465810","title":"Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis","phase":"","overall_status":"RECRUITING","enrollment_count":1850,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06338839","title":"Transthyretin Amyloidosis Cardiomyopathy in Patients With HFpEF in Russia","phase":"","overall_status":"TERMINATED","enrollment_count":1770,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02791230","title":"Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1733,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04561518","title":"ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT07207811","title":"CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1280,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT07052903","title":"TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1250,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT04108091","title":"Vyndaqel Capsules Special Investigation (ATTR-CM)","phase":"","overall_status":"COMPLETED","enrollment_count":1214,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06183931","title":"Study of ALXN2220 Versus Placebo in Adults With ATTR-CM","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1181,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06539169","title":"FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"xCures","has_results":false},{"nct_id":"NCT05772091","title":"Prognostic Value of Echocardiographic Parameters Based on Machine Learning Approach","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Pr. Nicolas GIRERD","has_results":false},{"nct_id":"NCT03842163","title":"Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology","phase":"","overall_status":"COMPLETED","enrollment_count":812,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07238426","title":"ATTRACT-52: Primary Care Cardiac Amyloidosis Screening in Ordu, Turkey","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":800,"lead_sponsor_name":"Kotyora Family Medicine Health Management and Education Association","has_results":false},{"nct_id":"NCT06414746","title":"Hereditary Transthyretin Amyloidosis Polyneuropathy in Patients With Carpal Tunnel Syndrome in Russia","phase":"","overall_status":"COMPLETED","enrollment_count":721,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06679946","title":"A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":700,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT04153149","title":"HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":655,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT03812172","title":"Screening for Cardiac Amyloidosis With Nuclear Imaging for Minority Populations","phase":"","overall_status":"COMPLETED","enrollment_count":646,"lead_sponsor_name":"Mathew S. Maurer, MD","has_results":true},{"nct_id":"NCT03860935","title":"Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":632,"lead_sponsor_name":"Eidos Therapeutics, a BridgeBio company","has_results":true},{"nct_id":"NCT05064839","title":"Imaging for the Evaluation of Transthyretin Cardiac Amyloidosis Prevalence of Patients Over 65 Hospitalized in Cardiology Wards (the IMPACT Study)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":553,"lead_sponsor_name":"Poitiers University Hospital","has_results":false},{"nct_id":"NCT05577819","title":"Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF","phase":"NA","overall_status":"RECRUITING","enrollment_count":515,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT02146378","title":"Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan)","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05489549","title":"Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT06360289","title":"Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT01994889","title":"Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":441,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03190577","title":"Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown Aetiology","phase":"NA","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT06101108","title":"Early Diagnosis of Age-Linked CArdiac TransThyRetin Amyloidosis by Selective Screening in Spinal Stenosis Surgery","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Philippe Debonnaire","has_results":false},{"nct_id":"NCT04988386","title":"Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":389,"lead_sponsor_name":"Eidos Therapeutics, a BridgeBio company","has_results":false},{"nct_id":"NCT03997383","title":"APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":360,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT06651073","title":"ATTR-CM: A Multi-country, Non-interventional Disease Registry","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":350,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04424914","title":"Global Prevalence of ATTR-CM in Participants With HFpEF","phase":"NA","overall_status":"TERMINATED","enrollment_count":347,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04563286","title":"Patient-Reported Outcome Measures in Wild-Type and Variant Cardiac Transthyretin Amyloidosis","phase":"","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"University of Messina","has_results":false},{"nct_id":"NCT04850105","title":"A Non-interventional Cohort Safety Study of Patients With hATTR-PN","phase":"","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Akcea Therapeutics","has_results":false},{"nct_id":"NCT03923920","title":"Screening for Systemic Amyloidosis Via the Ligamentum Flavum","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"The Cleveland Clinic","has_results":false},{"nct_id":"NCT07306949","title":"Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT01737398","title":"Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":173,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04136184","title":"NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":168,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03759379","title":"HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":164,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT06907186","title":"An Interventional Pilot Study to Investigate the Feasibility and Acceptance of a Structured Psychological Support Program for Patients, Caregivers, and Presymptomatic Carriers in Hereditary Transthyretin Amyloidosis With Cardiomyopathy","phase":"NA","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT05758493","title":"Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Oregon Health and Science University","has_results":false},{"nct_id":"NCT07170306","title":"Cardiac Amyloidosis in Patients With Aortic Stenosis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":143,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT02175004","title":"Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04513600","title":"ATTR-Cardiomyopathy Stabilization Following Tafamidis Therapy","phase":"","overall_status":"UNKNOWN","enrollment_count":131,"lead_sponsor_name":"The Christ Hospital","has_results":false},{"nct_id":"NCT07223203","title":"TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":125,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT04801329","title":"Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Cardiomyopathy","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":110,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04276220","title":"Prevalence of wtATTR-CM After Carpal Tunnel Release Surgery","phase":"NA","overall_status":"COMPLETED","enrollment_count":109,"lead_sponsor_name":"Steen Hvitfeldt Poulsen","has_results":false},{"nct_id":"NCT03886155","title":"Cardiac Amyloidosis Screening at Trigger Finger Release","phase":"","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"The Cleveland Clinic","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}